Study: NCT01831050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Oral Polio Vaccine (tOPV)
Description: Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.